Actelion announces change in its management structure
Otto Schwarz appointed Chief Operating Officer
Actelion Ltd announced that Otto Schwarz has been appointed Chief Operating Officer (COO). Otto Schwarz joined Actelion in 2008 as Head of Business Strategy & Operations. In addition to Commercial Operations and Business Strategy he assumes responsibility for Corporate Services, Global Quality Management and Corporate Communications, with all three departments retaining their respective Heads.
Actelion Executive Committee with five core members
Actelion has also adapted the membership of its Executive Committee (AEC), chaired by Jean-Paul Clozel, to the needs of a growing organization and to strengthen leadership and governance. The Executive Committee members comprise:
- Jean-Paul Clozel (Chief Executive Officer)
- Otto Schwarz (Chief Operating Officer, Executive VP)
- Andrew Oakley (Chief Financial Officer, Executive VP)
- Guy Braunstein (Head Global Clinical Development, Executive VP)
- Nicholas Franco (Chief Business Development Officer, Executive VP)
In addition to this core group, the extended AEC includes the following members:
- Christian Albrich (Head Global Human Resources, Senior VP)
- Marian Borovsky (Group General Counsel, Senior VP)
- Martine Clozel (Chief Scientific Officer, Senior VP)
- Roland Haefeli (Head Investor Relations and Public Affairs, Senior VP)
In line with the focus on strategic matters that includes driving innovation, the Chief Executive Officer will maintain the three co-heads of Research as direct reports: Beat Steiner (Drug Discovery, Biology), Thomas Weller (Drug Discovery, Chemistry) and Martine Clozel (Drug Discovery, Pharmacology and Preclinical Development).
The Group Compliance Officer, Peter Herrmann, will report to both the Chief Executive Officer as well as to the Nominating and Governance Committee of the Board of Directors, to ensure continued focus on corporate compliance.
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
EPO for the Brain - Engineered Moss produces human hormone without doping activity
ProtAffin AG granted patent in EU for CellJammer discovery technology - Novel technology enables development of a new class of biopharmaceuticals

CSIC researchers find the role of a protein in the regulation of synapse formation - The work raises the need for a balance between the Pinkman protein and the sHSPs proteins during the development of the nervous system for its correct formation
Affymetrix Selected to Genotype More Than 9,000 Framingham Heart Study Samples - SHARE Project to Help Identify Genetic Variants Associated With Heart, Lung, Blood and Sleep Disorders

New app calculates corona infection risk in rooms - Size of aerosol droplets that virus carriers release strongly influences infectivity
Northern_Norway_Pharmaceutical_Trust

Cell culture: The opportunities and the challenges - The promise of cell culture is accelerating demand, and emphasising the challenges, of this process
Crucell Teams up with ACE BioSciences and Harvard to Accelerate Bacterial Antibody Program
St_John_Ambulance_in_England_and_Wales
Harold_Ridley_(ophthalmologist)
Henry_Suter
